M. Klichinsky

发表

An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions.

Christina Leslie, Aaron Arvey, C. Leslie, 2012, Cell host & microbe.

Human chimeric antigen receptor macrophages for cancer immunotherapy

Martha E. Zeeman, Nicholas R. Anderson, Dylan M. Marchione, 2020, Nature Biotechnology.

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms

C. June, M. Wasik, M. Klichinsky, 2017, Leukemia.

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Carl H. June, C. June, J. Melenhorst, 2016 .

Dual CD 19 and CD 123 targeting prevents antigen-loss relapses after CD 19-directed immunotherapies

S. Grupp, D. Porter, M. Kalos, 2019 .

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

S. Grupp, D. Porter, M. Kalos, 2016, The Journal of clinical investigation.

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors

M. Klichinsky, S. Gill, Chris Sloas, 2021, Frontiers in Immunology.

Macrophage-Based Approaches for Cancer Immunotherapy A C

Nicholas R. Anderson, M. Klichinsky, S. Gill, 2021 .

Macrophage-Based Approaches for Cancer Immunotherapy

Nicholas R. Anderson, M. Klichinsky, S. Gill, 2020, Cancer Research.

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia

D. Porter, C. June, M. Klichinsky, 2015 .

Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model

C. June, J. Melenhorst, M. Klichinsky, 2017 .

194 Pre-clinical development of CT-1119, a mesothelin targeting chimeric antigen receptor macrophage (CAR-M), for solid tumor immunotherapy

Nicholas R. Anderson, M. Klichinsky, T. Condamine, 2022, Regular and Young Investigator Award Abstracts.

139 Chimeric antigen receptor macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD1 blockade in immunocompetent mouse models of HER2+ solid tumors

M. Klichinsky, T. Condamine, S. Abramson, 2021, Journal for ImmunoTherapy of Cancer.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Hans Bitter, Tyler J. Reich, Frederic D Bushman, 2018, Nature Medicine.

Abstract 1530: Anti-HER2 CAR monocytes demonstrate targeted anti-tumor activity and enable a single day cell manufacturing process

M. Klichinsky, T. Condamine, S. Abramson, 2021, Immunology.

Abstract 63: Chimeric antigen receptor macrophages (CAR-M) induce anti-tumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models

M. Klichinsky, T. Condamine, O. Shestova, 2021, Immunology.

a phase 1, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors

M. Klichinsky, E. Dees, J. Bauml, 2021 .

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

C. June, M. Feldman, A. Ziober, 2017, Cancer discovery.

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia

Adam Bagg, Cynthia E. Dunbar, Maksim Shestov, 2018, Cell.

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

M. Carroll, D. Porter, C. June, 2015, Leukemia.

Expression of inducible factors reprograms CAR-T cells for enhanced function and safety.

G. Linette, C. June, F. Sanvito, 2022, Cancer cell.

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma

M. Kalos, C. June, M. Wasik, 2016, Clinical Cancer Research.

EBV Latency Types Adopt Alternative Chromatin Conformations

I. Tempera, P. Lieberman, M. Klichinsky, 2011, PLoS pathogens.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

A fungal protease allergen provokes airway hyperresponsiveness in asthma

Zhihui Xie, K. Druey, R. Panettieri, 2015, Nature Communications.

A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.

E. Dees, M. Klichinsky, J. Bauml, 2021 .

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Tyler J. Reich, F. Bushman, S. Grupp, 2018, Nature Medicine.

Targeting CLEC12A with Chimeric Antigen Receptor T Cells Can Overcome the Chemotherapy Refractoriness of Leukemia Stem Cells

A. Bagg, C. June, Craig R Soderquist, 2017 .

Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms

C. June, J. Melenhorst, M. Wasik, 2016 .

Abstract 4575: Chimeric antigen receptor macrophages (CARMA) for adoptive cellular immunotherapy of solid tumors

C. June, M. Klichinsky, M. Ruella, 2017 .

315 Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508

R. Swaby, M. Klichinsky, T. Condamine, 2022, Regular and Young Investigator Award Abstracts.

633 A phase 1, first in human (FIH) study of autologous macrophages containing an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors

R. Swaby, M. Klichinsky, T. Condamine, 2022, Regular and Young Investigator Award Abstracts.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

951 A phase 1 first in human study of adenovirally transduced anti-HER2 CAR macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data

E. Dees, K. Reiss, M. Klichinsky, 2021, Journal for ImmunoTherapy of Cancer.

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

A. Bagg, C. June, M. Klichinsky, 2016 .